JD Health International Inc, a major Chinese online healthcare platform, is seeking to raise up to $3.5 billion in what is set to be Hong Kong's biggest initial public offering of the year, a term sheet showed.
The deal which could value the unit of e-commerce giant JD.com at nearly $29 billion when a greenshoe option is included comes during a good year for China's healthcare platforms which have seen their popularity surge in the wake of the coronavirus.
By comparison, its biggest competitor, Alibaba Health Information Technology, has a market capitalisation of around $34.6 billion.
JD Health plans to sell 381.9 million shares in a range of HK$62.80 and HK$70.58, according to the term sheet. A greenshoe option to sell a further 15% of stock would take the size of the IPO up to $4 billion.
According to its draft prospectus, JD Health is the largest online healthcare platform in China by revenue, logging 10.8 billion yuan ($1.6 billion) last year. It had 72.5 million annual active users as of June 30 compared to 53.5 million at the same time last year.
It is also China's largest online retail pharmacy with a 29.8% market share, according to a Frost & Sullivan report.
The fundraising is set to lay the groundwork for greater competition in China's healthcare market, said Zhen Zhou Toh, an Aequitas Research analyst.
"Raising money now is implying that they will be fighting to gain as much market share as possible in the near future, either by building out their network of offline and online pharmacies or increase its online presence by offering discounts," he wrote on the Smartkarma platform this month.
Six cornerstone investors led by GIC, Tiger Global and BlackRock have taken up to $1.35 billion worth of stock in the deal, the term sheet showed.
The book build begins on Wednesday and the shares are due to be priced on Tuesday.
The initial size of the deal represents 12.2% of JD Health's enlarged share capital and the greenshoe, if exercised, will take that to 13.8%.
JD Health shares are expected to start trading on Dec. 8.
The company did not immediately respond to a request for comment.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU